Systemic sclerosis: scleroderma

  • U.-F. Haustein


Systemic sclerosis is a chronic progressive disease in which features of Raynaud’s phenomenon and vascular occlusion are followed by sclerotic and fibrotic changes in the skin and internal organs. The average incidence is 8–12 patients per million population with a predominance of 3–4 females to one male.


Systemic Sclerosis Progressive Systemic Sclerosis Porphyria Cutanea Tarda Skin Score Localize Scleroderma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further reading

  1. Clements PJ, Furst DE, Wong W-K et al High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis. Arthritis Rheum 1999; 42: 1194–203.PubMedCrossRefGoogle Scholar
  2. Dziadzio M, Denton CP, Smith R et al Losartan therapy for Raynaud’s phenomenon and scleroderma. Arthritis Rheum 1999; 42: 2646–55.PubMedCrossRefGoogle Scholar
  3. Haustein U-F, Anderegg U. Pathophysiology of scleroderma: an update. J Eur Acad Dermatol Venereol 1998; 11: 1–8.PubMedCrossRefGoogle Scholar
  4. Haustein U-F, Mittag M. Zur Behandlung der systemischen Sklerodermie. Akt Dermatol 2000; 26: 271–7.Google Scholar
  5. Hunzelmann N, Anders S, Fierlbeck G et al Systemic scleroderma—multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol 1997; 133: 609–13.PubMedCrossRefGoogle Scholar
  6. Kerscher M, Meurer M, Sander C et al PUVA Bath photochemotherapy for localized scleroderma. Arch Dermatol 1996; 132: 1280–2.PubMedCrossRefGoogle Scholar
  7. Le CH, Morales A, Trentham DE. Minocycline in early diffuse scleroderma. Lancet 1998; 352: 1755–6.PubMedCrossRefGoogle Scholar
  8. McKown KM, Carbone LD et al Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 2000; 43: 1054–61.PubMedCrossRefGoogle Scholar
  9. Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J. Ultraviolet Al (340–400 nm) photo-therapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43: 670–4.CrossRefGoogle Scholar
  10. Pope JE. Treatment of systemic sclerosis. Rheum Dis Clin 1996; 2: 893–907.CrossRefGoogle Scholar
  11. Rook AH, Freundlich B, Nahass GT et al Treatment of autoimmune disease with extracorporal photochemotherapy: progressive systemic sclerosis. Yale J Bio Med 1989; 62: 639–45.Google Scholar
  12. Seibold JR, Korn JH, Simms R et al Recombinant human relaxin in the treatment of scleroderma. Ann Intern Med 2000; 132: 871–9.PubMedGoogle Scholar
  13. Sollberg S, Hunzelmann N, Roux M, Krieg T. Therapie der systemischen Sklerodermie. Z Haut Geschl Krankh 1994; 69: 6–14.Google Scholar
  14. Steen VD, Medsger RA, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma). A retrospective analysis. Ann Intern Med 1982; 97: 652–9.PubMedGoogle Scholar
  15. Stege H, Bernburg M, Humke S et al High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997; 36: 939–44.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • U.-F. Haustein

There are no affiliations available

Personalised recommendations